RSVVaxView

Adults 60+ RSV Vaccination Coverage

RSV vaccination coverage estimates among adults 60 years and older are based on data from CDC’s National Immunization Survey-Adult COVID Module. Estimates of vaccination coverage are based on respondent self-report.

• As of April 13, 2024, an estimated 23.8% (95% Confidence Interval: 23.0%-24.6%) of adults 60 years and older reported having received an RSV vaccine.
• An additional 10.0% (8.6%-11.4%) reported that they definitely plan to get vaccinated.
• White adults had higher vaccination coverage than adults in all other race and ethnicity groups, with coverage ranging from 9.5% (6.2%-12.7%) among Pacific Islander and Native Hawaiian adults to 25.9% (25.0%-26.9%) among non-Hispanic White adults.
• Vaccination coverage has also consistently varied by age, poverty status, health insurance status, urbanicity, sex, race and ethnicity, sexual orientation, gender identity, and chronic medical condition.
• Across states and the District of Columbia, receipt of an RSV vaccine was lowest in Mississippi [15.4% (12.0%-18.9%)] and highest in Michigan [34.8% (28.9%-40.7%)].
• Additional RSV vaccination data by demographic characteristics at the national level and overall estimates by jurisdiction are available.

Monthly Jurisdiction Vaccine Administration and Coverage (IIS)

RSV vaccination coverage estimates as of the end of February 2024 based on IIS data submitted to CDC by 52 immunization awardee jurisdictions.

• Among the currently reporting 44 state and city IIS jurisdictions, RSV vaccination coverage among adults 60 years and older ranged from 0.9% to 20.4%. Among 8 U.S. territorial and affiliated island jurisdictions, coverage ranged from 0.0% to 4.1%.

Adults 65 Years and Older (Medicare Fee-for-service) RSV Vaccination Coverage

RSV vaccination coverage among Medicare fee-for-service beneficiaries 65 years and older and enrolled in a Part D plan is assessed using data files from the Medicare Fee-For-Service administrative claims data managed by the Centers for Medicare & Medicaid Services.

• As of January 27, 2024, an estimated 18.7% of Medicare fee-for-service beneficiaries 65 years and older enrolled in Part D plan were vaccinated.
• Estimates by race and ethnicity group: 5.1% of Hispanic adults, 9.9% of Black, non-Hispanic adults, 19.5% of White, non-Hispanic adults, 18.3% of adults of Other, non-Hispanic race and ethnicity, and 14.3% of Asian, non-Hispanic adults were vaccinated.

RSV Vaccinations Administered in Pharmacies and Medical Offices (Data Source: IQVIA)

RSV vaccinations administered at retail pharmacies and American Medical Association (AMA) physicians’ medical offices for adults 60 years and older based on healthcare claims data.

• As of March 30, 2024, an estimated 10.02 million doses were administered in retail pharmacies and an estimated 338,643 doses were administered in physicians’ medical offices to adults 60 years and older.

Pregnant Persons RSV Vaccination Coverage

RSV vaccination coverage estimates for pregnant persons 18 to 49 years are based on data from CDC’s Vaccine Safety Datalink. Estimates of vaccination coverage are based on electronic health data from multiple integrated health systems.

The period of recommendation for maternal RSV vaccination ended for most of the continental U.S. on January 31, 2024, and data for pregnant persons will not be added beyond January 31, 2024. Estimates for prior weeks were updated for the final time on April 10 with data for pregnant persons who reached at least 32 weeks gestation and vaccinations received before January 31^st, 2024, that were identified retrospectively. Future data updates will resume in fall 2024.

• As of January 31, 2024, among persons who were pregnant and ≥32 weeks gestation since September 22, 2023, overall coverage with the RSV vaccine was 17.8%.
• Vaccination coverage was highest among non-Hispanic Asian (24.8%) pregnant persons and lowest among non-Hispanic Black (10.3%) pregnant persons.

Monthly Nirsevimab Coverage and Intent for Infants

Monthly nirsevimab coverage and intent estimates reported by females age 18-49 years with infants <8 months, females age 18-49 years who are currently pregnant, and females age 18-49 years who are currently trying to get pregnant, are based on data from CDC’s National Immunization Survey-Adult COVID Module. Estimates of nirsevimab coverage and intent are based on respondent self-report. The period of recommendation for the use of nirsevimab ended for most of the continental U.S. on March 31, 2024, and data will not be added beyond March 31, 2024. Future data updates will resume in fall 2024.

• As of March 2024, among females with an infant <8 months, 41.3% reported that their infant received nirsevimab.
• An additional 22.8% reported that they definitely plan to get nirsevimab for their infant.
• Among females who were pregnant in March, 46.3% reported that they definitely plan to get nirsevimab for their infant, and among females who are trying to get pregnant, 35.8% reported that they definitely plan to get nirsevimab for their infant.

Monthly Jurisdiction Nirsevimab Administration and Coverage (IIS)

Nirsevimab administration and coverage estimates among infants aged <8 months as of the end of February 2024 based on IIS data submitted to CDC by 52 immunization awardee jurisdictions. These data do not include doses administered to infants born on or after October 1, 2023, and information on maternal vaccination status is not reported and not considered when calculating nirsevimab coverage.

• Among the currently reporting 44 state and city IIS jurisdictions, nirsevimab coverage among infants <8 months ranged from 2.0% to 22.2%. Among 8 U.S. territorial and affiliated island jurisdictions, coverage ranged from 0.0% to 13.5%.